Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

In a nondescript office park in the northeast side of Menlo Park, CA, the next genomics revolution may be taking place. There, 12 prototypes of a new sequencing machine developed by startup Pacific Biosciences are churning out reams of DNA sequence as fast as built-in cameras can record it. The deep freezer-size boxes, covered for the time being in red plastic sheeting, are performing a novel feat: reading single strands of DNA in real time. The machine’s creators hope that innovation will result in a process that operates fast and cheaply enough to make sequencing a routine component of medical care.

The company, founded in 2004, made a splashy debut almost a year ago, showcasing its technology to the scientific community for the first time at a sequencing conference in Florida. Steve Turner, the company’s founder and chief technology officer, wowed the audience with a video of single molecule sequencing in progress, the product of a proof-of-principle experiment reading a 150-base-pair length of DNA. Since then, the startup has garnered $100 million more in funding–for a total of $178 million to date.

Pacific Biosciences’ central innovation is a small chip composed of a 100-nanometer-thick metal film deposited on a silicon-dioxide substrate and dotted with thousands of tiny wells, each only tens of nanometers in diameter. Before sequencing begins, an enzyme called DNA polymerase is immobilized at the bottom of the well, along with the strand of DNA to be read. Fluorescently labeled bases–each of the four DNA letters labeled with a different marker–are then flooded onto the plate, randomly diffusing into each well. When the correct base diffuses into the bottom of a well, the enzyme attaches it to the growing strand of DNA.

The wells are so small that fluorescent light shined through the bottom of the plate penetrates only the lower 20 to 30 nanometers of each well, meaning that only the bases being actively attached to the DNA molecule light up. That allows a camera to capture the sequencing reaction as it happens, leaving any irrelevant chemical activity in the dark. “The waveguide is the first technology to allow observation of the polymerase in action at physiologically relevant concentrations,” says Turner.

In a video showing the sequencing reactions in action, a series of lights scattered across the screen burst and fade in quick succession. (A computer detects which base is added with each burst by its position within a well.) The machines can currently sequence 12 million bases of DNA per hour, about one-third of a percent of a human genome. The video must actually be slowed to be viewed: the reactions occur too fast to be visible to the human eye.

Despite its early success, it’s not yet clear whether the company’s innovative approach will surpass “next generation” sequencing technologies already in use. Pacific Biosciences plans to release a commercial product in 2010 and will announce the target sequencing capacity for that machine early next year. New types of sequencing machines, such as those developed by Roche Applied Sciences and Illumina, have already revolutionized genomics, allowing scientists to sequence huge volumes of DNA and reportedly dropping the cost of a human genome to less than $100,000.

But Turner is confident that his method has advantages, especially in the clinical diagnostics market. The most advanced sequencing approaches currently on the market stop the sequencing reaction after the addition of each base, wash away extra bases, snap a picture, and then repeat. Real-time sequencing is faster and uses fewer chemicals, making it much cheaper. “In the long run, the reagent cost dominates in sequencing,” says Chad Nusbaum, codirector of the Genome Sequencing and Analysis program at the Broad Institute, in Cambridge, MA.

0 comments about this story. Start the discussion »

Credits: Pacific Biosciences

Tagged: Biomedicine, Business, DNA, sequencing, personalized medicine, $1000 genome, Pacific Biosciences

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me